{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-018908","form_type":"8-K","ticker":"INTS","cik":"0001567264","company_name":"INTENSITY THERAPEUTICS, INC.","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.808650+00:00","generated_at":"2026-05-23T08:06:00.603095+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"low","headline":"Intensity Therapeutics posts Q2 2025 corporate presentation; no new material data disclosed","bullets":["Presentation references lead candidate INT230-6 and DfuseRx platform for solid tumor treatment.","No specific clinical results, financial updates, or guidance changes are included in the filed excerpt.","Document furnished under Regulation FD; not deemed filed for SEC liability purposes."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-018908","json":"https://secwatch.observer/filing/0001628280-25-018908.json","markdown":"https://secwatch.observer/filing/0001628280-25-018908.md","text":"https://secwatch.observer/filing/0001628280-25-018908.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/0001628280-25-018908-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567264/000162828025018908/intensity-20250422.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:06:00.603095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}